Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Russo, Sam Nick
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate, DSP, Placebo	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	08/25	09/25
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder	Recruiting	3	150	Europe, Canada, US, RoW	Ecopipam, Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Syndrome	12/26	03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults	Completed	3	216	Europe, Canada, US, RoW	Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Disorder	01/25	02/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	11/26	11/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Russo, Sam Nick
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate, DSP, Placebo	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	08/25	09/25
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder	Recruiting	3	150	Europe, Canada, US, RoW	Ecopipam, Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Syndrome	12/26	03/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults	Completed	3	216	Europe, Canada, US, RoW	Ecopipam Hydrochloride	Emalex Biosciences Inc.	Tourette Disorder	01/25	02/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022	Recruiting	3	106	Europe, US	Dexamethasone sodium phosphate	Quince Therapeutics S.p.A., Biotrial	Ataxia Telangiectasia	11/26	11/26